Thrivent Financial For Lutherans Myriad Genetics Inc Transaction History

Thrivent Financial For Lutherans

  • $52.6 Billion
  • Q3 2024

A detailed history of Thrivent Financial For Lutherans transactions in Myriad Genetics Inc stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 109,216 shares of MYGN stock, worth $1.67 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
109,216
Previous 113,031 3.38%
Holding current value
$1.67 Million
Previous $2.77 Million 8.21%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024
SELL
$23.97 - $28.6 $91,445 - $109,109
-3,815 Reduced 3.38%
109,216 $2.99 Million
Q2 2024

Aug 13, 2024
SELL
$17.98 - $25.47 $59,190 - $83,847
-3,292 Reduced 2.83%
113,031 $2.77 Million
Q1 2024

May 14, 2024
SELL
$17.59 - $23.59 $38,785 - $52,015
-2,205 Reduced 1.86%
116,323 $2.48 Million
Q4 2023

Feb 14, 2024
BUY
$13.91 - $21.32 $30,254 - $46,371
2,175 Added 1.87%
118,528 $2.27 Million
Q3 2023

Nov 14, 2023
SELL
$15.99 - $23.22 $49,760 - $72,260
-3,112 Reduced 2.6%
116,353 $1.87 Million
Q2 2023

Aug 14, 2023
BUY
$17.56 - $23.76 $687,632 - $930,417
39,159 Added 48.76%
119,465 $2.77 Million
Q1 2023

May 17, 2023
SELL
$15.26 - $23.75 $42,941 - $66,832
-2,814 Reduced 3.39%
80,306 $1.87 Million
Q4 2022

Feb 08, 2023
SELL
$14.51 - $20.99 $3,395 - $4,911
-234 Reduced 0.28%
83,120 $1.21 Million
Q3 2022

Nov 14, 2022
BUY
$18.21 - $27.88 $80,488 - $123,229
4,420 Added 5.6%
83,354 $1.59 Million
Q2 2022

Aug 16, 2022
BUY
$16.45 - $25.88 $229,082 - $360,404
13,926 Added 21.42%
78,934 $1.43 Million
Q1 2022

May 13, 2022
BUY
$22.67 - $28.01 $476 - $588
21 Added 0.03%
65,008 $1.64 Million
Q4 2021

Feb 16, 2022
BUY
$24.13 - $32.63 $45,702 - $61,801
1,894 Added 3.0%
64,987 $1.79 Million
Q3 2021

Nov 15, 2021
BUY
$29.97 - $36.66 $3,086 - $3,775
103 Added 0.16%
63,093 $2.04 Million
Q2 2021

Aug 19, 2021
BUY
$25.39 - $32.61 $30,645 - $39,360
1,207 Added 1.95%
62,990 $1.93 Million
Q1 2021

May 17, 2021
SELL
$19.92 - $31.6 $9,362 - $14,852
-470 Reduced 0.75%
61,783 $1.88 Million
Q4 2020

Feb 16, 2021
BUY
$12.16 - $19.77 $3,708 - $6,029
305 Added 0.49%
62,253 $1.23 Million
Q3 2020

Nov 10, 2020
SELL
$11.25 - $14.75 $256,218 - $335,931
-22,775 Reduced 26.88%
61,948 $808,000
Q2 2020

Aug 12, 2020
BUY
$10.69 - $16.49 $630 - $972
59 Added 0.07%
84,723 $961,000
Q1 2020

May 15, 2020
BUY
$9.78 - $29.53 $248,724 - $751,006
25,432 Added 42.94%
84,664 $1.21 Million
Q4 2019

Feb 13, 2020
BUY
$20.93 - $35.1 $8,016 - $13,443
383 Added 0.65%
59,232 $1.61 Million
Q3 2019

Nov 14, 2019
BUY
$22.08 - $47.08 $30,161 - $64,311
1,366 Added 2.38%
58,849 $1.69 Million
Q2 2019

Aug 13, 2019
BUY
$22.67 - $35.0 $8,455 - $13,055
373 Added 0.65%
57,483 $1.6 Million
Q1 2019

May 14, 2019
BUY
$26.93 - $34.7 $113,590 - $146,364
4,218 Added 7.97%
57,110 $1.9 Million
Q4 2018

Feb 15, 2019
SELL
$27.23 - $45.56 $63.2 Million - $106 Million
-2,319,634 Reduced 97.77%
52,892 $1.54 Million
Q3 2018

Nov 15, 2018
SELL
$37.57 - $50.34 $18.2 Million - $24.4 Million
-484,320 Reduced 16.95%
2,372,526 $109 Million
Q2 2018

Aug 14, 2018
BUY
$27.75 - $40.17 $223,165 - $323,047
8,042 Added 0.28%
2,856,846 $107 Million
Q1 2018

May 08, 2018
BUY
$28.83 - $41.01 $1.11 Million - $1.57 Million
38,368 Added 1.37%
2,848,804 $84.2 Million
Q4 2017

Feb 14, 2018
BUY
$28.45 - $37.14 $23,784 - $31,049
836 Added 0.03%
2,810,436 $96.5 Million
Q3 2017

Nov 14, 2017
BUY
$24.01 - $36.2 $67.5 Million - $102 Million
2,809,600
2,809,600 $102 Million

Others Institutions Holding MYGN

# of Institutions
253
Shares Held
90.9M
Call Options Held
100K
Put Options Held
34K
View Full List

About MYRIAD GENETICS INC

MYGN Quotes by TradingView
  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.23B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email